Gilder Gagnon Howe & CO LLC Tg Therapeutics, Inc. Transaction History
Gilder Gagnon Howe & CO LLC
- $8.56 Billion
- Q4 2024
A detailed history of Gilder Gagnon Howe & CO LLC transactions in Tg Therapeutics, Inc. stock. As of the latest transaction made, Gilder Gagnon Howe & CO LLC holds 81,292 shares of TGTX stock, worth $2.9 Million. This represents 0.03% of its overall portfolio holdings.
Number of Shares
81,292
Previous 64,898
25.26%
Holding current value
$2.9 Million
Previous $1.52 Million
61.24%
% of portfolio
0.03%
Previous 0.02%
Shares
3 transactions
Others Institutions Holding TGTX
# of Institutions
372Shares Held
85.5MCall Options Held
3.78MPut Options Held
3M-
Vanguard Group Inc Valley Forge, PA15.6MShares$556 Million0.01% of portfolio
-
Black Rock Inc. New York, NY11.4MShares$406 Million0.0% of portfolio
-
State Street Corp Boston, MA9.2MShares$328 Million0.01% of portfolio
-
Geode Capital Management, LLC Boston, MA3.19MShares$114 Million0.01% of portfolio
-
Pictet Asset Management Holding Sa Carouge, V82.79MShares$99.5 Million0.09% of portfolio
About TG THERAPEUTICS, INC.
- Ticker TGTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 145,274,000
- Market Cap $5.17B
- Description
- TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...